Description: If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for

Description: Biogen’s fair value estimate has seen a modest uptick, now set at $178.07 compared to the previous $176.72. This change reflects slightly improved analyst confidence, supported by optimism around policy headwinds and progress in the company’s drug pipeline. Stay tuned to discover how investors can monitor these evolving narratives as market sentiment shifts. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Biogen. What Wall...

Description: The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks. Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation. Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.

Description: Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.

Description: BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.

Description: LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha

Description: Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.

Description: The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.

Description: Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car

Description: A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.

Description: Investing.com -- Biogen shares could benefit from Novo Nordisk’s Phase III Evoke/Evoke+ trials failure, according to analysts at Jefferies.

Description: Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s immunology strategy by broadening its early-stage pipeline and incorporating an additional clinically validated modality into its expanding immunology capabilities CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop or

Description: TORONTO & CAMBRIDGE, Mass., November 24, 2025--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious diseases. The company has secured more than $70 million in committed funding, including a collaboration with Biogen Inc. that will provide $50 million in upfront capital, as well as an equity commitment from Versant.

Description: Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority immunological targets."

Description: In November 2025, Biogen received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of a high dose nusinersen regimen for 5q spinal muscular atrophy, with a final European Commission decision expected by January 2026. This regulatory progress not only has the potential to expand treatment options for SMA patients in Europe but also strengthens Biogen’s position within the neurological disease treatment market. We'll...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: November has been NO-vember when it comes to tech stocks. Investors are shunning artificial-intelligence leaders and other momentum names. Investors seem to be embracing drug stocks, insurers, and medical equipment companies again.

Description: New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatment, and real-world experienceBiogen is committed to deepening scientific understanding of Alzheimer’s disease, including therapeutic delivery and disease progression CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at th

Description: FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.

Description: Biogen (BIIB) and Stoke Therapeutics just published final results from the two-year BUTTERFLY study. The data highlights that neurodevelopment in Dravet syndrome patients plateaus at around age two, despite currently available therapies. See our latest analysis for Biogen. Biogen’s share price has gained real momentum in recent weeks, climbing 15.2% in the past month and 18.6% over the last 90 days, after a prolonged period of lackluster returns. Despite a recent flurry of product news and...

Description: The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio

Description: Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Description: – Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urgent need for new medicines that target the underlying genetic cause of Dravet syndrome to improve long-term outcomes – CAMBRIDGE, Mass. and BEDFORD, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Thera

Description: BEDFORD, Mass., & CAMBRIDGE, Mass., November 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study in people with Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent

Description: ThecaFlex DRx is an implantable device designed to improve treatment options for patients with neurological disorders.

Description: Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1Final European Commission decision expected in January 2026SMA is a rare, genetic, neuromuscular disease that affects individuals of all ages2 CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human

Description: CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ThecaFlex DRx™ is an investigational implantable device designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines, which could ease both patient experience and access

Description: TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare product

Description: DelveInsight's Antibody-mediated Rejection Market Insights report includes a comprehensive understanding of current treatment practices, antibody-mediated rejection emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: Biogen recently reported third quarter 2025 earnings results that surpassed expectations, with revenue rising to US$2.53 billion and net income increasing to US$466.5 million compared to a year ago, fueled by strong sales from newly launched therapies such as LEQEMBI, SKYCLARYS, and ZURZUVAE. This performance helped offset declines in Biogen's established multiple sclerosis franchise and prompted renewed analyst confidence in the company’s evolving drug portfolio. We'll explore how Biogen’s...

Description: Wondering if Biogen stock is priced for opportunity or risk? You are not alone. There is a lot more beneath the surface to consider when assessing its true value. Recently, Biogen’s share price has seen a modest climb, up 4.8% over the past week and 3.0% in the last month. However, it is still down 9.9% over the past year, pointing to both shifting expectations and evolving market sentiment. Several headlines have caught investor attention, including new clinical trial partnerships and...

Description: Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls

Description: Pre-Market Futures: The futures are trading modestly higher on Thursday after a big snap-back rally on Wednesday, as all the major indices staged a solid rebound following the Tuesday sell-off. While some of the buying was likely “Buy the Dip” investors doing what has come naturally for the last three years, another possible tailwind was ... Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More

Description: Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.

Description: Biogen’s third quarter results came in ahead of Wall Street’s revenue and profit expectations, driven by robust performance from recently launched products and continued strength in its multiple sclerosis portfolio. Management attributed much of the growth to LEQEMBI, SKYCLARYS, and ZURZUVAE, which together posted significant year-on-year gains. CEO Christopher Viehbacher highlighted that “launch products again in this quarter, and if I look at this year-to-date as well, more than have offset th

Description: The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.

Description: Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding of its disease modifying potentialExhibitor Spotlight to discuss role of CD38 cells across a range of immune-mediated kidney diseasesFelzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated

Description: Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.

Description: Biogen (BIIB) delivered a notable turnaround this year, posting EPS growth of 32.1% after five years of average annual declines of 20.5%. Net profit margins improved to 15.3% from last year’s 12%. Forecasts now call for earnings to grow at 7.3% per year, even as revenue is expected to decline at a 0.8% annual rate over the next three years. With shares trading at $149.61, well below the estimated fair value of $333.62 and a price-to-earnings ratio of 14.3x compared to the industry average of...

Description: Biogen (BIIB) shares have shown some movement recently, and investors may be taking a closer look at what is driving performance. Over the past month, the stock has dipped around 3%. See our latest analysis for Biogen. While Biogen’s share price has dipped nearly 3% over the past month, the bigger picture shows momentum has faded, with a 90-day share price return of over 13% but a disappointing 1-year total shareholder return of -14%. That mix of short-term growth and long-term declines...

Description: Biogen Inc (BIIB) reports robust financial performance with significant growth in launch products and a focus on expanding its pipeline for future success.

Description: Two of Biogen's key growth drivers hit snags in the third-quarter. But Biogen stock yo-yoed and, most recently, edged down slightly.

Description: Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.

Description: Biogen stock’s consensus analyst price target has ticked up slightly, moving from $172.34 to $172.55. This adjustment reflects fresh optimism around the company’s growth prospects, as well as nuanced shifts in both bullish and bearish analyst outlooks. Investors will want to follow closely to understand how changing views and upcoming catalysts could continue shaping Biogen’s story in the months ahead. Stay updated as the Fair Value for Biogen shifts by adding it to your watchlist or...

Description: Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.

Description: While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.

Description: Biogen cut its full-year adjusted-earnings expectations, though third-quarter profit rose on strength from its Alzheimer’s drug and rare-disease treatments.

Description: Biogen (BIIB) delivered earnings and revenue surprises of +23.65% and +8.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Investing.com -- Biogen Inc. (NASDAQ:BIIB) shares fell 2.6% after the biotech company cut its full-year earnings guidance despite reporting better-than-expected third quarter results, with adjusted earnings and revenue surpassing analyst estimates.

Description: BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 18 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 117.2 million which is an increase of approximately 68 percent compared to the royalty obtained by BioArctic for the third quarter 2024.

Description: Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to look for.

Description: Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathologyTOKYO and CAMBRIDGE, Mass., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO

Description: Biogen and partner UCB recently announced upcoming presentations at the American College of Rheumatology 2025 conference highlighting positive Phase 3 data for dapirolizumab pegol in treating systemic lupus erythematosus (SLE), supported by efficacy across multiple endpoints and promising safety data, especially in women of childbearing age. This follows a series of pipeline enhancements for Biogen in immunology and rare diseases, including a new licensing agreement with Vanqua Bio for a...

Description: The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

Description: Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.

Description: The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to address a

Description: While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Description: Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: DelveInsight's Glomerulonephritis Market Insights report includes a comprehensive understanding of current treatment practices, glomerulonephritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the suc

Description: Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality of lifePresentation of preclinical study of DZP showing minimal to no human placental transfer CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug

Description: RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.

Description: PISCATAWAY, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- IMPALA, a global consortium dedicated to advancing digital and analytics-driven quality in biopharmaceutical development, announced the appointment of Ann Marie Dunne, Global Head of R&D Quality and Compliance at Biogen, as its new Chair. She succeeds Jonathan Taylor, Vice President and Global Head of Product Development Quality at Roche, who has served as Chair since IMPALA’s inception. Known for her ability to bridge innovation and execution,